7,580 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by Stamos Capital Partners L.P.

Stamos Capital Partners L.P. bought a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 7,580 shares of the medical research company's stock, valued at approximately $1,490,000.

Other institutional investors also recently added to or reduced their stakes in the company. Sagespring Wealth Partners LLC acquired a new stake in IQVIA during the fourth quarter worth about $913,000. Crux Wealth Advisors bought a new position in IQVIA in the fourth quarter worth $1,301,000. Qtron Investments LLC increased its holdings in IQVIA by 70.0% in the 4th quarter. Qtron Investments LLC now owns 5,616 shares of the medical research company's stock valued at $1,104,000 after buying an additional 2,313 shares during the period. Jaffetilchin Investment Partners LLC acquired a new stake in shares of IQVIA during the 4th quarter valued at about $1,493,000. Finally, Treasurer of the State of North Carolina lifted its stake in IQVIA by 0.6% during the fourth quarter. Treasurer of the State of North Carolina now owns 79,272 shares of the medical research company's stock worth $15,578,000 after purchasing an additional 500 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Down 3.2 %

Shares of IQV stock traded down $4.78 during trading on Friday, reaching $143.66. The company's stock had a trading volume of 3,302,597 shares, compared to its average volume of 1,403,069. The business has a fifty day moving average price of $177.57 and a 200-day moving average price of $197.47. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The company has a market cap of $25.33 billion, a price-to-earnings ratio of 19.15, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently commented on IQV. Morgan Stanley boosted their price target on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Barclays reissued an "equal weight" rating and issued a $170.00 target price (down from $235.00) on shares of IQVIA in a report on Thursday, April 10th. Stephens began coverage on shares of IQVIA in a research report on Friday, December 20th. They set an "overweight" rating and a $250.00 price target on the stock. Robert W. Baird dropped their price objective on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, January 21st. Finally, Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Six investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and a consensus target price of $241.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.